Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
Go back to Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting| (NASDAQ: RVMD) | Delayed: 165.81 +2.82 (1.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $162.99 | 52 Week High | $ | |||
| Open | $162.32 | 52 Week Low | $ | |||
| Day High | $166.84 | P/E | N/A | |||
| Day Low | $162.15 | EPS | $ | |||
| Volume | 3,128,201 | |||||
